End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
- AUD | -.--% | -.--% | -.--% |
04-19 | INOVIQ Concludes Analytical Validation for Ovarian Cancer Blood Test | MT |
04-15 | Fears of Middle East Conflict Escalation Quell Appetite for Australian Shares | MT |
Business Summary
Sales per Business
AUD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Human Telomerase Reverse Transcriptase
91.2
%
| 0 | 99.0 % | 0 | 91.2 % | +32.61% |
Molecular Nets
8.8
%
| 0 | 1.0 % | 0 | 8.8 % | +1,128.37% |
Sales per region
AUD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
South Korea
60.4
%
| 0 | 1.0 % | 0 | 60.4 % | +8,350.67% |
United States
39.6
%
| 0 | 99.0 % | 0 | 39.6 % | -42.49% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Leearne Hinch
CEO | Chief Executive Officer | - | 06/11/16 |
Mark Edwards
DFI | Director of Finance/CFO | - | 01/11/22 |
Gregory Rice
CTO | Chief Tech/Sci/R&D Officer | - | 19/09/21 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 70 | 11-28 | |
Philip Powell
BRD | Director/Board Member | 65 | 17/06/19 |
Geoff Cumming
BRD | Director/Board Member | - | 27/07/20 |
Robert Johnston
BRD | Director/Board Member | - | 17/06/19 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 92,018,702 | 65,958,065 ( 71.68 %) | 0 | 71.68 % |
Company contact information
Sector
Sales per Business
Sales per region
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+31.27% | 49.46B | |
+1.91% | 42.58B | |
+48.88% | 42.49B | |
-5.26% | 29.09B | |
+12.81% | 26.61B | |
-23.67% | 18.64B | |
+7.89% | 13.16B | |
+31.00% | 12.55B | |
+23.81% | 12.1B |
- Stock Market
- Equities
- IIQ Stock
- BD1 Stock
- Company BAR1 LIFE